Skip to contentC
Collegium Pharmaceutical, Inc
C
COLLCollegium Pharmaceutical, Inc Q4 2022 · 10-K
Revenue$129.62M$129.62M+373.7% vs Q4 2021 Net Income-$7.20M-$7.20MN/M vs Q4 2021 EPS Diluted-$0.21-$0.21N/M vs Q4 2021 Gross Profit$49,789,000N/M Operating Income
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Collegium Pharmaceutical, Inc · CIK 1267565 · Engraved from SEC EDGAR
Operating Cash Flowderived$66,325,000+83.2% Free Cash Flowderived$65,385,000+83.2% Margins · derivedGross margin38.4%+43.3 pt vs Q4 2021
Operating margin9.1%+133.8 pt vs Q4 2021
Net margin-5.6%+85.9 pt vs Q4 2021
ended Dec 31, 2022 · filed Feb 23, 2023 · 54 d after period end